June 21, 2013
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX).
The investigation focuses on whether Dynavax made materially false and misleading statements regarding the viability of HEPLISAV, the Company's lead product candidate. Specifically, the investigation focuses on whether Dynavax failed to disclose: (i) that the clinical trial for HEPLISAV was flawed in that it was not representative of
the United States
population and did not provide information regarding concurrent use of HEPLISAV with other vaccines; and (ii) the Company did not provide the Food and Drug Administration ("FDA") with adequate information regarding HEPLISAV manufacturing processes and controls.
June 10, 2013
, Dynavax issued a press release announcing that the FDA would require additional safety trials prior to granting approval of HEPLISAV. Following this news, Dynavax's stock price dropped
Request more information now by clicking here: www.faruqilaw.com/DVAX
. There is no cost or obligation to you.
If you invested in Dynavax stock or options between
April 26, 2012
June 10, 2013
and would like to discuss your legal rights, visit
. You can also contact us by calling
toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to
Faruqi & Faruqi, LLP also encourages anyone with information regarding Dynavax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (
). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP369 Lexington Avenue, 10th Floor
New York, NY
Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330